Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 11; p. 1853
• Main Authors: Nicholson, Martin W, Ting, Chien-Yu, Chan, Darien Z H, Cheng, Yu-Che, Lee, Yi-Chan, Hsu, Ching-Chuan, Huang, Ching-Ying, Hsieh, Patrick C H
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.06.2022; MDPI
• Subjects: Alzheimer's disease; Animal models; Cardiac arrhythmia; Cardiomyocytes; Cardiomyopathy; Cell culture; Cell lines; Cell therapy; Clinical trials; Dopamine; Drug development; Gene expression; Heart; induced pluripotent stem cells; Inhibitory postsynaptic potentials; Kinases; Molecular modelling; Mutation; Neurodegeneration; neurons; Oxidative stress; Parkinson's disease; Patients; Phenotypes; Pluripotency; Potassium; Proteins; Regenerative medicine; Review; Stem cell transplantation; Stem cells; cardiomyocytes; induced pluripotent stem cells; neurons; cell therapy
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11111853

The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the molecular mechanisms of human disease, drug discovery, and regenerative medicine. As such, the use of iPSCs in drug development and validation has shown a sharp increase in the past 15 years. Furthermore, many labs have been successful in reproducing many disease phenotypes, often difficult or impossible to capture, in commonly used cell lines or animal models. However, there still remain limitations such as the variability between iPSC lines as well as their maturity. Here, we aim to discuss the strategies in generating iPSC-derived cardiomyocytes and neurons for use in disease modeling, drug development and their use in cell therapy.